Fish oil products are available with or without prescription and are widely used by patients with ischaemic heart disease (IHD). The interest in fish oils, rich in the long chain n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (n-3 20:5) and docosahexaenoic acid (n-3 22:6), originates primarily from the pioneering work of Dyerberg and Bang.' Prompted by the low incidence of acute myocardial infarction in Eskimos in Greenland they suggested that a very high dietary intake of n-3 PUFA's from marine food offered protection against IHD. They showed that the Eskimos had a beneficial lipid pattern and that their balance between pro-aggregatory thromboxanes and anti-aggregatory prostacyclins was shifted towards an anti-thrombotic state compared with Danes.' There is also evidence from Japan and Holland that dietary intake of fishprotects against IHD.2 In the American MRFIT study the daily intake of n-3 PUFA was inversely related to IHD mortality in middle-aged men.3 However, no such relation was found in the American Physicians' Health Study. 4 Experimental studies of atherogenesis and arterial thrombogenesis in various animal species lend some support to the hypothesis that dietary intake of n-3 PUFA's may play a part in primary or secondary prevention of IHD or both.5 but probably also because of increased synthesis of prostacyclins.59 Studies in pigs indicated that n-3 PUFAs can stimulate the synthesis of endothelium-derived relaxing factor.'0 This may contribute to the favourable change in the interaction between platelets and the vessel wall and may also be partly responsible for the reduction in blood pressure shown after dietary supplementation with n-3 PUFA in patients with mild hypertension." 12 The risk of clinically significant episodes of bleeding is very low2 13-probably lower than after a low dose of aspirin.
The synthetic activity of leucocytes is reduced after intake of fish oil mainly because the production of bioactive leukotrienes is decreased. ' 27 28 whereas no such effect was found in three.242629 Table 1 shows that the design of the studies varied in terms of the dose of n-3 PUFA. It seems logical to start treatment with n-3 PUFA at least one week before PTCA to ensure cellular incorporation of n-3 PUFAs by the time of the procedure. This was done in only two of the studies.2328 Some of the studies were hampered by the lack of angiographic end points.252629 In our opinion systematic angiography is mandatory, preferably six months after PTCA (or before when symptoms occur). Computer-assisted analysis of the degree of stenosis is preferable.
Though the recent study by Bairati et al 28 may be criticised because of a high exclusion rate of patients, it fulfils these criteria. In this study fish oil supplementation significantly reduced the incidence of restenosis.28
Furthermore, a dietary intake of >0-15 g/day n-3 PUFA was also associated with a lower frequency of restenosis.28 In the study by Nye et al supplementation with n-3 PUFA reduced the frequency of restenosis compared with placebo, but was not better than combination therapy with aspirin/dipyridamole.2' In some of the other studies all the patients were on permanent aspirin treatment.23 26 29 In a recent meta-analysis of seven randomised trials22-28 O'Connor et al 13 reported a significant reduction in the rate of restenosis in the patients treated with fish oil (odds ratio = 0O71; 95% confidence interval 0-54 to 0 94; p = 0-016 (two tailed)). O'Connor et al concluded that this was compatible with a small to moderate benefit of fish oil but that the result requires confirmation in a single randomised clinical trial with a large number of patients.
CORONARY BYPASS SURGERY
In a preliminary report on fish oil a daily dose of 4-5 g n-3 PUFA was compared with low dose aspirin. There was no difference in the frequency of late vein graft occlusion between the two groups.30 DOSE AND SOURCE OF n-3 PUFA In the studies in which fish oil supplements have been given to patients with IHD the daily dose of n-3 PUFA usually has been 2-7 g. Studies on the effect of fish oil on the rate of restenosis after PTCA do not suggest that the possible inhibition of restenosis was related to the dose of n-3 PUFA given. The exact dose of n-3 PUFA given in the DART study20 is not known, but on average the mean daily dose did not exceed 1 g. Some of the potential beneficial biochemical and cellular effects of fish oil supplementation are dose dependent,2 and at present the optimal daily dose of n-3 PUFA is unknown.
Fish oil supplementation and consumption of fish are different approaches. When a fish meal is eaten the amount of n-3 PUFA's varies with the type of fish eaten ( 
